These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12123487)

  • 1. Influence of the angiotensin-converting enzyme gene insertion/deletion polymorphism on lipoprotein/lipid response to gemfibrozil.
    Bossé Y; Vohl MC; Dumont M; Brochu M; Bergeron J; Després JP; Prud'homme D
    Clin Genet; 2002 Jul; 62(1):45-52. PubMed ID: 12123487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides.
    Nerbrand C; Nyberg P; Nordström L; Samsioe G
    Maturitas; 2002 May; 42(1):55-62. PubMed ID: 12020980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
    Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM
    Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
    Farnier M; Salko T; Isaacsohn JL; Troendle AJ; Dejager S; Gonasun L
    Am J Cardiol; 2003 Oct; 92(7):794-7. PubMed ID: 14516878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study.
    Marian AJ; Safavi F; Ferlic L; Dunn JK; Gotto AM; Ballantyne CM
    J Am Coll Cardiol; 2000 Jan; 35(1):89-95. PubMed ID: 10636265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy.
    Nemeth A; Szakmary K; Kramer J; Dinya E; Pados G; Fust G; Huettinger M
    Eur J Clin Chem Clin Biochem; 1995 Nov; 33(11):799-804. PubMed ID: 8620056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD
    Arch Intern Med; 2000 Apr; 160(8):1177-84. PubMed ID: 10789612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study.
    Vahlquist C; Olsson AG; Lindholm A; Vahlquist A
    Acta Derm Venereol; 1995 Sep; 75(5):377-80. PubMed ID: 8615057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA; Fanghänel-Salmón G; Meza E; Montes J; Gulías-Herrero A; Sánchez L; Monterrubio-Flores EA; González-Valdez H; Gómez Pérez FJ
    Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
    Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme gene polymorphism, lipids, and apolipoproteins in menopausal women on hormone replacement therapy.
    Cubrilo-Turek M; Sertić J; Duraković Z
    Acta Med Croatica; 2001; 55(4-5):161-7. PubMed ID: 12398019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia.
    Aberg F; Appelkvist EL; Bröijersén A; Eriksson M; Angelin B; Hjemdahl P; Dallner G
    Eur J Clin Invest; 1998 Mar; 28(3):235-42. PubMed ID: 9568470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil.
    Bossé Y; Pascot A; Dumont M; Brochu M; Prud'homme D; Bergeron J; Després JP; Vohl MC
    Genet Med; 2002; 4(4):311-5. PubMed ID: 12172398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
    Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
    JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of an insertion/deletion polymorphism of angiotensin converting enzyme gene on the changes of serum lipid ratios and blood pressure induced by a high-carbohydrate and low-fat diet].
    Zhang RR; Song YY; Fan M; Li YH; Jiang Z; Zhang Z; Fang DZ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 44(5):731-5. PubMed ID: 24325100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.
    Samuelsson O; Attman PO; Knight-Gibson C; Kron B; Larsson R; Mulec H; Weiss L; Alaupovic P
    Nephron; 1997; 75(3):286-94. PubMed ID: 9069450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.
    Syvänne M; Nieminen MS; Frick MH; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Ehnholm C; Taskinen MR
    Circulation; 1998 Nov; 98(19):1993-9. PubMed ID: 9808595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men.
    Dumont M; Mauriège P; Bergeron J; Després JP; Prud'homme D
    Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1136-43. PubMed ID: 11477498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia.
    Yang CY; Gu ZW; Xie YH; Valentinova NV; Yang M; Yeshurun D; Quion JA; Gotto AM
    Atherosclerosis; 1996 Sep; 126(1):105-16. PubMed ID: 8879439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.
    Stalenhoef AF; de Graaf J; Wittekoek ME; Bredie SJ; Demacker PN; Kastelein JJ
    Atherosclerosis; 2000 Nov; 153(1):129-38. PubMed ID: 11058707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.